Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ICML 2019 | Single agent ibrutinib produces long-term disease control in Waldenström’s: the pivotal trial

Steven Treon • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the final report of the pivotal trial of ibrutinib monotherapy for previously treated Waldenström’s macroglobulinemia (NCT01614821). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Steven Treon

The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia 1:18
The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
Steven Treon • 19 Jun 2025
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis 1:13
Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
Steven Treon • 19 Jun 2025
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session 2:56
Exciting developments in Waldenström’s macroglobulinemia: insights from a ‘Meet the Expert’ session
Steven Treon • 19 Jun 2025
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients 1:49
Treatment approaches for symptomatic, treatment-naive WM versus previously treated patients
Steven Treon • 19 Jun 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals